Top Markets
#1 Siren Siren +33.94%
#2 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +23.71%
#3 Ribbita by Virtuals Ribbita by Virtuals +18.13%
#4 Wiki Cat Wiki Cat +17.37%
#5 PulseChain PulseChain +16.92%
#6 Cysic Cysic +16.47%
#7 Velvet Velvet +16.43%
#8 Bitway Bitway +16.27%
#9 KUB Coin KUB Coin +15.77%
#10 Wrapped Bitcoin (PulseChain) Wrapped Bitcoin (PulseChain) +15.36%
Coin of the day
Siren Siren
設定
言語
日本
通貨
USD
テーマ
NeuroSense Therapeutics Ltd. NeuroSense Therapeutics Ltd.

NeuroSense Therapeutics Ltd.

NRSN
株式のランク #31255
NeuroSense Therapeutics Ltd. operates as a biotechnology firm in the clinical... NeuroSense Therapeutics Ltd. operates as a biotechnology firm in the clinical development phase, committed to discovering and developing effective therapies for individuals suffering from severe neurodegenerative conditions. The company's leading drug candidate, PrimeC, is an innovative oral formulation that has successfully concluded Phase IIa clinical investigations for the management of amyotrophic lateral sclerosis (ALS). Additionally, its early-stage research pipeline features StabiliC, a potential treatment for Parkinson's disease, and CogniC, which is under development for Alzheimer's disease. Established in 2017, NeuroSense Therapeutics Ltd. is headquartered in Herzliya, Israel.
株価
$0.39
時価総額
$13.79M
変化（1日）
-13.53%
変化（1年）
-68.80%
国
IL
取引 NeuroSense Therapeutics Ltd. (NRSN)

カテゴリー

Healthcare
NeuroSense Therapeutics Ltd.（NRSN）のP/B比率
2026 時点のP/B比率 TTM: 0
NeuroSense Therapeutics Ltd. の最新の財務報告および株価によると、現在のP/B比率（TTM）は 0 です。2026 年末時点でのP/B比率は 0 でした。
NeuroSense Therapeutics Ltd. の P/B 比率の履歴（2026 ～ 2026）
各年末時点のP/B比率
年 P/B比率 変化
提供された日付のデータは十分ではありません。
同業他社のP/B比率
企業 P/B比率 P/B比率の差 国
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 6.3419 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 6.2413 -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 2.5054 -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 3.4612 -
BE